Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002)Alessandro D. Santin, Michael J. Birrer, Samir N. Khleif et al.|Gynecologic Oncology|2020Cited by 155